Quantitative proteomic analysis of HER2 protein expression in PDAC tumors

Metastatic pancreatic adenocarcinoma (PDAC) is the third leading cause of cancer-related death in the United States, with a 5-year survival rate of only 11%, necessitating identification of novel treatment paradigms. Tumor tissue specimens from patients with PDAC, breast cancer, and other solid tumo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical proteomics 2024-03, Vol.21 (1), p.24-24, Article 24
Hauptverfasser:	Randall, Jamie, Hunt, Allison L, Nutcharoen, Aratara, Johnston, Laura, Chouraichi, Safae, Wang, Hongkun, Winer, Arthur, Wadlow, Raymond, Huynh, Jasmine, Davis, Justin, Corgiat, Brian, Bateman, Nicholas W, Deeken, John F, Petricoin, Emanuel F, Conrads, Thomas P, Cannon, Timothy L
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma Analysis Antibodies Antineoplastic drugs Biological products Biomarkers Biopsy Breast cancer Cancer Cancer therapies Care and treatment Chemotherapy Cloning Correspondence Diagnosis Drugs ErbB-2 protein Fish Health aspects Kinases Laboratories Lysates Malignancy Metastases Metastasis Neoplasms Pancreas Pancreatic cancer Patients Phosphorylation Protein arrays Protein expression Proteins Proteomics Response rates Solid tumors Survival Therapeutic targets Tumor cells Tumors Viral antibodies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!